<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
    <head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <meta http-equiv="Content-Style-Type" content="text/css" />
        <meta name="generator" content="pandoc" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
                        <title></title>
        <style type="text/css">code{white-space: pre;}</style>
                                                    <style>
            body {
                font-family: Georgia;
                max-width: 800px;
                margin: 0 auto;
                line-height: 30px;
                font-size: 18px;
                padding-left: 350px;
                padding-right: 50px;
                color: #111;
            }
            
            h1, h2, h3, h4, h5, h6 {
                font-family: Arial;
            }
            
            h1 {
                padding-top: 200px;
                line-height: 50px;
            }
            h2 {
                padding-top: 30px;
            }
            h3 {
                padding-top: 20px;
            }
            h4 {
                padding-top: 10px;
            }
            p {
                text-align: justify;
            }
            p a {
                word-wrap: break-word;
                white-space: pre;
            }
            code {
                word-wrap: break-word;
            }
            blockquote {
                border-left: 3px solid #eee;
                margin-left: 20px;
                padding-left: 20px;
            }
            
            ::selection {
                background-color: #E4E4E4;
            }
            
            table {
                width: 100%;
            }
            table caption {
                font-weight: bold;
            }
            table tr {
                padding: 0;
                margin: 0;
                background-color: #f0f0f0;
            }
            table tr.even {
                background-color: #fafafa;
            }
            table td {
                margin: 0;
                padding: 3px 5px;
            }
            
            p span.added {
                color: green;
                background-color: #FFF3C5;
            }
            p span.removed {
                color: red;
                background-color: #FFF3C5;
            }
            
            #title-page {
                padding: 80px 0;
            }
            
            #TOC {
                position: fixed;
                left: 0;
                top: 0;
                overflow-y: scroll;
                height: 100%;
                background: #fafafa;
                max-width: 300px;
                font-family: Arial;
                font-size: 15px;
                line-height: 30px;
            }
            ::-webkit-scrollbar {
                width: 8px;
            }
            ::-webkit-scrollbar-track {
                background-color: #ECECEC;
            }
            ::-webkit-scrollbar-thumb {
                background-color: #B0B0B0;
                border-radius: 8px;
            }
            #TOC > ul {
                padding-right: 10px;
            }
            #TOC ul {
                list-style: none;
                padding-left: 20px;
            }
            #TOC ul li a {
                text-decoration: none;
                color: #364149;
                text-overflow: ellipsis;
                display: block;
                white-space: nowrap;
                overflow: hidden;
            }
            #TOC ul li a:hover {
                color: #008cff;
            }
            
            .figure {
                text-align: center;
            }
            .figure p {
                text-align: center;
                font-style: italic;
            }
            .figure img {
                  width: 100%;
            }
            </style>
                <script src="js/jquery.js"></script>
        <script src="js/diff.js"></script>
        <script src="js/main.js"></script>
    </head>
    <body>
                <!--
                -->
        <div id="title-page">
            <h1>Is occupational asbestos exposure an under-recognised cause of idiopathic pulmonary fibrosis?</h1>
            <h2>Carl Jonathan Reynolds</h2>
        </div>
                    <div id="TOC">
                <ul>
                <li><a href="#abstract">Abstract</a></li>
                <li><a href="#acknowledgements">Acknowledgements</a></li>
                <li><a href="#list-of-figures">List of figures</a></li>
                <li><a href="#list-of-tables">List of tables</a></li>
                <li><a href="#abbreviations">Abbreviations</a></li>
                <li><a href="#introduction-to-thesis"><span class="toc-section-number">1</span> Introduction to thesis</a><ul>
                <li><a href="#occupational-asbestos-exposure-as-an-underecognised-cause-of-idiopathic-pulmonary-fibrosis"><span class="toc-section-number">1.1</span> Occupational asbestos exposure as an underecognised cause of idiopathic pulmonary fibrosis</a></li>
                <li><a href="#aims-and-objectives"><span class="toc-section-number">1.2</span> Aims and objectives</a></li>
                </ul></li>
                <li><a href="#data-sources"><span class="toc-section-number">2</span> Data sources</a><ul>
                <li><a href="#outline-of-thesis"><span class="toc-section-number">2.1</span> Outline of thesis</a></li>
                </ul></li>
                <li><a href="#literature-review-and-meta-analysis"><span class="toc-section-number">3</span> Literature review and meta-analysis</a><ul>
                <li><a href="#introduction"><span class="toc-section-number">3.1</span> Introduction</a></li>
                <li><a href="#method"><span class="toc-section-number">3.2</span> Method</a></li>
                <li><a href="#results"><span class="toc-section-number">3.3</span> Results</a></li>
                <li><a href="#discussion"><span class="toc-section-number">3.4</span> Discussion</a></li>
                <li><a href="#conclusion"><span class="toc-section-number">3.5</span> Conclusion</a></li>
                </ul></li>
                <li><a href="#mortality-analysis"><span class="toc-section-number">4</span> Mortality analysis</a><ul>
                <li><a href="#introduction-1"><span class="toc-section-number">4.1</span> Introduction</a></li>
                <li><a href="#method-1"><span class="toc-section-number">4.2</span> Method</a></li>
                <li><a href="#results-1"><span class="toc-section-number">4.3</span> Results</a></li>
                <li><a href="#discussion-1"><span class="toc-section-number">4.4</span> Discussion</a></li>
                <li><a href="#conclusion-1"><span class="toc-section-number">4.5</span> Conclusion</a></li>
                </ul></li>
                <li><a href="#asbestos-exposure-assessment"><span class="toc-section-number">5</span> Asbestos exposure assessment</a><ul>
                <li><a href="#introduction-2"><span class="toc-section-number">5.1</span> Introduction</a></li>
                <li><a href="#method-2"><span class="toc-section-number">5.2</span> Method</a></li>
                <li><a href="#results-2"><span class="toc-section-number">5.3</span> Results</a></li>
                <li><a href="#discussion-2"><span class="toc-section-number">5.4</span> Discussion</a></li>
                <li><a href="#conclusion-2"><span class="toc-section-number">5.5</span> Conclusion</a></li>
                </ul></li>
                <li><a href="#genetic-susceptibility-in-ipf"><span class="toc-section-number">6</span> Genetic susceptibility in IPF</a><ul>
                <li><a href="#introduction-3"><span class="toc-section-number">6.1</span> Introduction</a></li>
                <li><a href="#method-3"><span class="toc-section-number">6.2</span> Method</a></li>
                <li><a href="#results-3"><span class="toc-section-number">6.3</span> Results</a></li>
                <li><a href="#discussion-3"><span class="toc-section-number">6.4</span> Discussion</a></li>
                <li><a href="#conclusion-3"><span class="toc-section-number">6.5</span> Conclusion</a></li>
                </ul></li>
                <li><a href="#idiopathic-pulmonary-fibrosis-job-exposures-study-ipfjes"><span class="toc-section-number">7</span> Idiopathic pulmonary fibrosis job exposures study (IPFJES)</a><ul>
                <li><a href="#introduction-4"><span class="toc-section-number">7.1</span> Introduction</a></li>
                <li><a href="#method-4"><span class="toc-section-number">7.2</span> Method</a></li>
                <li><a href="#results-4"><span class="toc-section-number">7.3</span> Results</a></li>
                <li><a href="#discussion-4"><span class="toc-section-number">7.4</span> Discussion</a></li>
                <li><a href="#conclusion-4"><span class="toc-section-number">7.5</span> Conclusion</a></li>
                </ul></li>
                <li><a href="#conclusion-5"><span class="toc-section-number">8</span> Conclusion</a><ul>
                <li><a href="#thesis-summary"><span class="toc-section-number">8.1</span> Thesis summary</a></li>
                <li><a href="#future-work"><span class="toc-section-number">8.2</span> Future work</a></li>
                </ul></li>
                <li><a href="#appendix-1-ipf-epidemiology-code">Appendix 1: IPF epidemiology code</a></li>
                <li><a href="#appendix-2-ipfjes-study-documentation">Appendix 2: IPFJES study documentation</a></li>
                <li><a href="#references">References</a></li>
                </ul>
            </div>
                                
<!-- This page is for an official declaration. -->
<p>   </p>
<h1 id="abstract" class="unnumbered">Abstract</h1>
<!-- This is the abstract -->
<p>The question of whether occupational asbestos exposure is an under-recognized cause of idiopathic pulmonary fibrosis arises because it is clinically plausible, epidemiologically plausible, and consistent with fibre studies and case-control data. This thesis examines the question by means of a literature review and a novel hospital based case-control study, the idiopathic pulmonary fibrosis job exposures study (IPFJES).</p>
<p> </p>
<h1 id="acknowledgements" class="unnumbered">Acknowledgements</h1>
<!-- This is for acknowledging all of the people who helped out -->
<p>I am grateful to Zeinab, Ada, and Rosa for putting up with me.</p>
<p>I am grateful to Paul, Chris, and Sara for their supervision.</p>
<p>I am grateful to the partcipants, to Rupa and all of the principle investigators and their teams for making the study happen.</p>
<!-- Use the \newpage command to force a new page -->




<h1 id="list-of-figures" class="unnumbered">List of figures</h1>
<!--
For me, this was the only drawback of writing in Markdown: it is not possible to add a short caption to figures and tables. This means that the \listoftables and \listoffigures commands will generate lists using the full titles, which is probably isn't what you want. For now, the solution is to create the lists manually, when everything else is finished.
-->
<p>Figure 4.1 This is an example figure . . . <br />
Figure x.x Short title of the figure . . . </p>
<p> </p>

<h1 id="list-of-tables" class="unnumbered">List of tables</h1>
<!-- 
For me, this was the only drawback of writing in Markdown: it is not possible to add a short caption to figures and tables. This means that the \listoftables and \listoffigures commands will generate lists using the full titles, which is probably isn't what you want. For now, the solution is to create the lists manually, when everything else is finished.
-->
<p>Table 5.1 This is an example table . . . <br />
Table x.x Short title of the figure . . . </p>
<h1 id="abbreviations" class="unnumbered">Abbreviations</h1>
<ul>
<li><strong>IPF</strong> Idiopathic pulmonary fibrosis.</li>
<li><strong>MUC5B</strong> Mucin 5B gene.</li>
</ul>

<p> </p>
<h1 id="introduction-to-thesis"><span class="header-section-number">1</span> Introduction to thesis</h1>
<h2 id="occupational-asbestos-exposure-as-an-underecognised-cause-of-idiopathic-pulmonary-fibrosis"><span class="header-section-number">1.1</span> Occupational asbestos exposure as an underecognised cause of idiopathic pulmonary fibrosis</h2>
<p>Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic lung disease which in 2012 was the recorded cause of death for c.4000 people in England and Wales. Its incidence, currently around 7.5/100,000 person-years, has increased by 5% pa since 2000.<span class="citation">[1]</span> The pathophysiology of IPF is complex, the outcome of host susceptibility factors, epithelial injury, and a dysregulated repair process. Several gene polymorphisms which result in a vulnerable alveolar epithelium have been characterized; they include abnormalities in mucin genes (eg MUC5B), surfactant protein genes, and telomerase genes (eg TERT and TERC).<span class="citation">[2]</span><span class="citation">[3]</span><span class="citation">[4]</span> The median age of onset is 70 years and the condition is more common in men (M:F ratio 1.6), manual workers, and those living in industrial areas<span class="citation">[1]</span>, patterns that are not unique to the UK.<span class="citation">[3]</span> The prognosis is poor, with a median survival of three years.<span class="citation">[5]</span><span class="citation">[6]</span></p>
<p>These epidemiological distributions of IPF are consistent with a long-latency response to occupational dust exposure; in particular, the incidence of IPF correlates strongly (if ecologically) with historic asbestos use.<span class="citation">[7]</span> Mineralogical studies support the concept of asbestosis-IPF misclassification by revealing high fibre burdens in the lung tissue of patients diagnosed with 'IPF' and revision of the diagnosis to 'asbestosis'.<span class="citation">[8]</span><span class="citation">[9]</span><span class="citation">[10]</span><span class="citation">[11]</span></p>
<p>Identification of occupational asbestos fibre exposure as an under-recognised cause of IPF is important to improve our understanding of the aetio-pathophysiology of IPF and the accuracy of prognostic information. It would have implications for compensation and impact on the current restrictions on individual treatment. Importantly, it would inform evidence-based workplace exposure policies in the UK and internationally, particularly in the many countries with continuing high levels of asbestos use.</p>
<h2 id="aims-and-objectives"><span class="header-section-number">1.2</span> Aims and objectives</h2>
<p>My overall aim is to characterize and measure asbestos exposure as an occupational determinant of IPF; additionally, I will determine host-exposure interactions mediated by candidate susceptibility polymorphisms (in particular MUC5B promoter polymorphism rs35705950).</p>
<p>My specific research questions are:</p>
<ol style="list-style-type: decimal">
<li>Does a dose-response relationship exist for occupational asbestos exposure and IPF?</li>
<li>Does the presence of asbestos exposure modify the association between IPF and rs35705950?</li>
</ol>
<h1 id="data-sources"><span class="header-section-number">2</span> Data sources</h1>
<ul>
<li>For the literature review and meta-analysis of occupational exposures in IPF I consider all published IPF case-control studies reporting on occupational exposures.</li>
<li>For the mortality analysis I use data obtained from the Office of National Statistics, Health and Safety Executive, and the World Health Organisation Mortality Database.</li>
<li>Brief reviews of asbestos exposure assessment and genetic suceptibility in IPF rely on the published literature.</li>
<li>Primary case-control data collected during my PhD as part of the idiopathic pulmonary fibrosis job exposures study (IPFJES) is used to analyze asbestos exposure in IPF. (?include navaratum case control jobs data that was shared)</li>
</ul>
<h2 id="outline-of-thesis"><span class="header-section-number">2.1</span> Outline of thesis</h2>
<p>This chapter (Chapter 1) describes the problem studied, aims and objectives, and approach. Chapter 2 is a literature review and meta-analysis of IPF case-control studies that report on occupational exposure. Chapter 3 is an analysis of IPF and asbestos related disease mortality data. Chapter 4 is a review of asbestos exposure assessment methodology. Chapter 5 is a review of genetic suceptibility in IPF. Chapter 6 describes the idiopathic pulmonary fibrosis job exposures study including results and analysis arising from it. Chapter 7 concludes the thesis by summarising it and suggesting future work.</p>
<h1 id="literature-review-and-meta-analysis"><span class="header-section-number">3</span> Literature review and meta-analysis</h1>
<!--
consider 'finishing off' lit search stuff and sticking more detail in here  - ?build a django app?    

consider revisiting meta-analysis using R and reviewing with cosetta
-->
<h2 id="introduction"><span class="header-section-number">3.1</span> Introduction</h2>
<p>Idiopathic pulmonary fibrosis (IPF) is a diagnosis of exclusion. It is made in the presence of a usual interstitial pneumonitis (UIP) pattern on high resolution CT scan or biopsy. The diagnosis requires that known causes of interstitial lung disease (such as drug toxicity, connective tissue disease, domestic, and occupational or environmental exposures) be excluded.<span class="citation">[12]</span></p>
<p>Attributing a disease process to a specific exposure can be difficult. Disease processes are frequently complex or multifactorial, depending on the interaction of genetic and environmental components. Well-studied and relatively frequent entities such as chronic obstructive pulmonary disease, ischaemic heart disease and diabetes lend themselves to epidemiologic investigation, delineating the major risk factors for disease and their relative contributions to risk at the population level. IPF presents an additional challenge to attribution; because of its relative infrequency, epidemiologic study of the disease is largely limited to case-control studies.<span class="citation">[13]</span> Studying specific occupational exposures also presents its own challenges; co-exposure is common, occupational hygeine data is frequently limited and self-reported exposure is prone to recall bias.</p>
<p>I identified several review articles of the epidemiology of interstitial lung disease that do not necessarily focus on IPF and only briefly mention occupational factors (e.g Ley2013<span class="citation">[3]</span>. Here I consider review articles that specifically deal with occupational factors in IPF and cite the case-control studies used.</p>
<p>Turner-Warwick (1998) discusses potential difficulties in establishing attribution and causality in IPF. She observes that there is variation in clinical practice with respect to the standard applied to exclude IPF; some clinicians exclude IPF when exposure to a potential cause is identified, others only when there is clear exposure to an established cause. She explains that diagnosis based on radiologic and clinical findings, and not on lung biopsy or bronchioalveolar lavage, may result in initiating agents for disease being overlooked. Further, that exposures such as asbestos, silica, coal, graphite, hard metal, and avian proteins, may result in disease that can not be differentiated from IPF.<span class="citation">[14]</span></p>
<p>Reviewing the epidemiology of IPF and case-control studies to date Hubbard (2001) describes the association of IPF with occupational exposures to metal and wood and estimates that 10% of IPF cases may be due to occupational metal exposure and 5% of cases to wood.<span class="citation">[15]</span></p>
<p>Taskar and Coultas (2006) review and carry out a meta-analysis of six case-control studies investigating environmental and occupational exposures in IPF. They report population attributable risk percentages for agriculture and farming (20.8%), livestock (4.1%), wood dust (5%), metal dust (3.4%), stone/sand/silica (3.5%), and smoking (49.1%).<span class="citation">[16]</span></p>
<p>Gulati and Redlich’s (2015) review of exposures causing usual interstitial pneumonia highlights that asbestosis may appear indistinguishable from IPF and summarises previous case-control studies but did not pool studies to perform a meta-analysis.<span class="citation">[17]</span></p>
<p>I sought to identify and meta-analyze all IPF case-control studies dealing with occupational exposures.</p>
<h2 id="method"><span class="header-section-number">3.2</span> Method</h2>
<p>Pubmed, embase, and google scholar search engines were searched for combinations of the terms 'idiopathic pulmonary fibrosis', 'occupation', 'case-control study' and synonyms. When relevant papers were identified papers referenced and papers citing the paper were reviewed. Medline ranker<span class="citation">[18]</span> and bespoke pubmed 'mining' techniques<span class="citation">[19]</span> were also used.</p>
<p>Two investigators independently reviewed and abstracted data for five exposure categories common to the identified case-control studies: “vapors, gases, dusts, and/or fumes (VGDF)”, “metal dust”, “wood dust”, “silica dust”, and “agricultural dust”. We calculated PAF as follows: PAF=pc(OR - 1)/OR, where pc is the proportion of cases exposed and OR is the risk estimate.</p>
<p>We calculated pooled OR and pooled PAF for occupational exposures using fixed effects models and random effects models in Stata. When there was results of the models differed substantively, we used the results of the fixed effects model, which were more conservative. The pooled PAF relied on the ratio of attributable cases to all cases underlying each risk estimate.</p>
<h2 id="results"><span class="header-section-number">3.3</span> Results</h2>
<p>We found (as of May 2017) 14 case-control studies looking at occupational exposures in IPF (Table 3.1) the most recent review article covers only eight of them. Associations with metal, wood, silica, and agricultural dust were reported. <span class="citation">[20]</span><span class="citation">[21]</span> <span class="citation">[22]</span> <span class="citation">[23]</span> <span class="citation">[24]</span> <span class="citation">[25]</span> <span class="citation">[26]</span> <span class="citation">[27]</span> <span class="citation">[28]</span> <span class="citation">[29]</span> <span class="citation">[30]</span> <span class="citation">[31]</span></p>
<p>43 risk estimates from 14 publications (2027 IPF cases in total) were used. Each exposure category was assessed with 6-11 risk estimates (Table 3.2).</p>


<h2 id="discussion"><span class="header-section-number">3.4</span> Discussion</h2>
<p>tables above will need updating becaue of gremlins</p>
<p>Our results support the case for a proportion of IPF cases being attributable to occupational exposures.</p>
<p>Pooled ORs were significantly elevated for VGDF, metal dust, wood dust, agricultural dust, and silica dust; the pooled PAF estimates by category ranged from 4-23%. This is an important finding for an otherwise idiopathic disease which carries significant morbidity and mortality; identifying causal occupational agents would permit remidiation and prevention.</p>
<p>Associations between IPF and wood, metal, and agricultural dust were previouly reported in a meta-analysis of six case-control studies by Taskar and Coultas. <span class="citation">[16]</span> While our findings are similar we found a smaller effect size for agricultural exposure and a large effect size for non-specific vapours, gases, dust, and fumes (VGDF), see Table 3.2.</p>
<p>Funnel plot asymmetry using Egger's test, which may be due to publication bias, was present for VGDF (p = 0.04) and metal dust (p = 0.03) but not for wood dust (p = 0.09), silica dust (p = 0.2), and agricultural dust (p = 0.6). However, the number of studies included is small and funnel plot assymetry may be due to chance rather than bias.</p>
<p>There are several limitations to the meta-analysis that arise from the case-control studies included.</p>
<p>Several studies <span class="citation">[20]</span> <span class="citation">[32]</span> <span class="citation">[24]</span> <span class="citation">[26]</span> <span class="citation">[28]</span> used population controls but do not provide details on participation rates. Participation rates can be low for community controls; a recent UK case-control study investigating prothrombotic factors in IPF reported a response rate of 28% for commumnity controls. <span class="citation">[33]</span> This approach is vulnerable to non-responder bias. One study<span class="citation">[34]</span> used employee occupational records and death certificates from pension-fund records for a single company and was only able to locate the occupational records for 40% of cases and 38% of controls.</p>
<p>Nearly all studies relied on self-reported exposures rather than life time occupational histories to assess exposure; an approach that is prone to recall bias and does not permit examination of dose-response relationships.</p>
<p>Reliance of self-reported exposures also means that studies are potentially vulnerable to confounding as a result of co-exposure. For example, several studies have described strong associations between metal work and IPF and specify sheet metal workers<span class="citation">[21]</span><span class="citation">[20]</span><span class="citation">[34]</span>, a group who are frequently exposed to dust containing asbestos fibres<span class="citation">[35]</span> and who in a recent UK study, had the highest risk of mesothelioma.<span class="citation">[36]</span></p>
<p>Case definitions and sources for cases varied between studies. For example Scott (1990)<span class="citation">[20]</span> used a case definition which included a chest radiograph showing bilateral interstitial shadowing whereas most other studies relied on high resolution CT. Four studies used mortality data <span class="citation">[21]</span><span class="citation">[37]</span><span class="citation">[26]</span><span class="citation">[34]</span> to identify cases and one study<span class="citation">[26]</span> used a national register of patients recieving oxygen therapy. Differences in healthcare coverage and coding practices can result in selection bias.<span class="citation">[38]</span></p>
<h2 id="conclusion"><span class="header-section-number">3.5</span> Conclusion</h2>
<p>The observed excess risk could represent disease misclassification of pneumoconiosis or hypersensitivity pneumonitis, but this is unlikely to fully explain the observed effects. Our analysis supports an etiologic role for occupational exposures in IPF, potentially explaining up to 23% of the burden of disease and highlighting a role for workplace exposure reduction in disease prevention.</p>
<h1 id="mortality-analysis"><span class="header-section-number">4</span> Mortality analysis</h1>
<h2 id="introduction-1"><span class="header-section-number">4.1</span> Introduction</h2>
<p>The incidence of Idiopathic pulmonary fibrosis (IPF) has been increasing at a rate of 5% per annum since 2000. By definition, the diagnosis of IPF is not made in the presence of an identifiable cause. However, the distribution of the disease in the population (more common in men, manual workers, and those living in more industrial areas of the country) suggests a causal contribution from an occupational or environmental source.</p>
<p>It is hypothesised that a proportion of Idiopathic Pulmonary Fibrosis (IPF) cases are due to occult environmental or occupational exposures to asbestos dust. This would be expected to result in a spatio-temporal association between IPF, Mesothelioma, and Asbestosis mortality patterns coinciding with asbestos exposure. It would also be expected to produce a birth cohort effect</p>
<!-- 
what sort of spatio-temporal association is seen for mesothelioma? this is fundamentally same problem as mapping meso. revisit when have done meso work.    

should add correlation coefficient and poisson regression results

should revisit with cosetta support and perhaps after have done some reading
-->
<p>Our aim was to examine trends in IPF, Mesothelioma, and Asbestosis mortality data for evidence of cohort effect and association.</p>
<h2 id="method-1"><span class="header-section-number">4.2</span> Method</h2>
<p>Regional age and sex stratified mortality data for IPF, Mesothelioma, and Asbestosis were obtained for England and Wales from the Office of National Statistics for the period 1974–2012. Data were age-standardised and visualised using the Python Pandas data analysis library and matplotlib.</p>
<h2 id="results-1"><span class="header-section-number">4.3</span> Results</h2>
<p>IPF mortality continues to rise. Female:Male is approximately 1:1.6. There are more IPF deaths in the North West and South East of England. IPF mortality does appear to correlate with mesothelioma mortality (Figure ). There is evidence of a cohort effect with age-specific IPF death rates increasing in successive cohorts, most clearly seen from age 60 (Figure ). While overall rates were higher for men but there were not marked sex differences in cohort mortality trends.</p>
<div class="figure">
<img src="source/figures/ipfasbmesomaletrend.jpg" alt="IPF, mesothelioma, and asbestosis mortality trends " style="width:50.0%" />
<p class="caption">IPF, mesothelioma, and asbestosis mortality trends </p>
</div>
<div class="figure">
<img src="source/figures/ipfmalebirthcohorts.jpg" alt="IPF male birth cohorts " style="width:50.0%" />
<p class="caption">IPF male birth cohorts </p>
</div>
<h2 id="discussion-1"><span class="header-section-number">4.4</span> Discussion</h2>
<p>icd coding chat</p>
<p>This is the discussion. Duis ultrices tempor sem vitae convallis. Pellentesque lobortis risus ac nisi varius bibendum. Phasellus volutpat aliquam varius. Mauris vitae neque quis libero volutpat finibus. Nunc diam metus, imperdiet vitae leo sed, varius posuere orci.</p>
<h2 id="conclusion-1"><span class="header-section-number">4.5</span> Conclusion</h2>
<p>Conclusions: The birth cohort effect we observed is consistent with a proportion of IPF cases being due to an occupational or environmental exposure with latency and further research is needed.</p>
<h1 id="asbestos-exposure-assessment"><span class="header-section-number">5</span> Asbestos exposure assessment</h1>
<h2 id="introduction-2"><span class="header-section-number">5.1</span> Introduction</h2>
<p>Most previous work has relied on self-reported workplace exposure information, an approach that is open to recall bias and deals poorly with confounding.</p>
<p>Lifetime occupational histories are more accurately recalled than self-reported workplace exposures and can be combined with measures such as mesothelioma occupational mortality proportionate mortality (PMR) estimates and job-process assessments to minimize recall bias and more accurately characterise cumulative exposures. <span class="citation">[39]</span><span class="citation">[40]</span><span class="citation">[41]</span><span class="citation">[36]</span> This allows too the examination of `exposure-response' relationships, entirely lacking in the published literature.</p>
<h2 id="method-2"><span class="header-section-number">5.2</span> Method</h2>
<h2 id="results-2"><span class="header-section-number">5.3</span> Results</h2>
<h2 id="discussion-2"><span class="header-section-number">5.4</span> Discussion</h2>
<h2 id="conclusion-2"><span class="header-section-number">5.5</span> Conclusion</h2>
<h1 id="genetic-susceptibility-in-ipf"><span class="header-section-number">6</span> Genetic susceptibility in IPF</h1>
<h2 id="introduction-3"><span class="header-section-number">6.1</span> Introduction</h2>
<p>Third, advances in our understanding of IPF susceptibility now permit study of host-exposure interactions. The minor-allele of the rs35705950 SNP in the mucin 5B gene was found to be present in 38% of IPF patients but just 9% of controls.<span class="citation">[42]</span> The polymorphism results in excess MUC5B protein in the airway, impaired clearance of inhaled substances and a chronic inflammatory burden on the alveolar surface.<span class="citation">[42]</span> The association is allele dose-dependent, has been replicated in independent cohorts, and appears to confer improved survival.<span class="citation">[3]</span><span class="citation">[42]</span><span class="citation">[43]</span> Two large GWASs have confirmed the observed associations of IPF with MUC5B and other loci.<span class="citation">[44]</span><span class="citation">[45]</span></p>
<h2 id="method-3"><span class="header-section-number">6.2</span> Method</h2>
<p>Vivamus consectetur, velit in congue lobortis, massa massa lacinia urna, sollicitudin semper ipsum augue quis tortor. Donec quis nisl at arcu volutpat ultrices. Maecenas ex nibh, consequat ac blandit sit amet, molestie in odio. Morbi finibus libero et nisl dignissim, at ultricies ligula pulvinar.</p>
<p>C</p>
<h2 id="results-3"><span class="header-section-number">6.3</span> Results</h2>
<h2 id="discussion-3"><span class="header-section-number">6.4</span> Discussion</h2>
<p>This is the discussion. Etiam sit amet mi eros. Donec vel nisi sed purus gravida fermentum at quis odio. Vestibulum quis nisl sit amet justo maximus molestie. Maecenas vitae arcu erat. Nulla facilisi. Nam pretium mauris eu enim porttitor, a mattis velit dictum. Nulla sit amet ligula non mauris volutpat fermentum quis vitae sapien.</p>
<h2 id="conclusion-3"><span class="header-section-number">6.5</span> Conclusion</h2>
<p>This is the conclusion to the chapter. Nullam porta tortor id vehicula interdum. Quisque pharetra, neque ut accumsan suscipit, orci orci commodo tortor, ac finibus est turpis eget justo. Cras sodales nibh nec mauris laoreet iaculis. Morbi volutpat orci felis, id condimentum nulla suscipit eu. Fusce in turpis quis ligula tempus scelerisque eget quis odio. Vestibulum et dolor id erat lobortis ullamcorper quis at sem.</p>
<h1 id="idiopathic-pulmonary-fibrosis-job-exposures-study-ipfjes"><span class="header-section-number">7</span> Idiopathic pulmonary fibrosis job exposures study (IPFJES)</h1>
<h2 id="introduction-4"><span class="header-section-number">7.1</span> Introduction</h2>
<p>My study will be a multi-centre, hospital-outpatient, incident case-control study. Participants will be recruited from a UK network of six confirmed centres. Cases will be men who present, between 07.2017 and 07.2019, with a new diagnosis of IPF consistent with standard criteria<span class="citation">[46]</span>; they will be identified monthly by the MDT coordinator of participating centres.<span class="citation">[47]</span></p>
<p>For each case, four controls, frequency-matched on age, will be randomly selected from incident outpatient attendances (not confined to respiratory) who do not have a diagnosis of IPF and are from the hospital as the case. Monthly lists of outpatient attendances will be obtained using the patient administration systems of participating centres. 120 cases and 480 controls will be recruited over two years with four participants enrolled and interviewed per day.</p>
<p>Eligible participants will be contacted by telephone and invited to participate. An interviewer will collect data on demographics, lifetime occupational history, hobbies, family medical history, and smoking using a structured web-based questionnaire designed by us to collect lifetime occupational histories. This approach will facilitate coding, allow input validation, and permit questions to be tailored to pre-specified conditions. The questions will be developed in collaboration with an international expert in asbestos exposure measurement, Dr John Cherrie of the IOM. Participants will be invited to provide a venous blood sample for genetic analysis.</p>
<p>Cases and controls will be genotyped using a panel of 15 pre-defined candidate susceptibility SNPs including rs35705950. Genotyping will be undertaken using Q-PCR and Taqman assays on DNA isolated from whole blood samples.</p>
<p>For the primary analysis unconditional logistic regression will be used to analyse 'any' vs 'no' asbestos exposure and categories of cumulative exposure adjusting for age and smoking status. Prior data<span class="citation">[36]</span> indicate that the probability of exposure among controls is 0.29. If the true OR for disease in exposed subjects relative to unexposed subjects is 2.0, I will need to recruit 94 case patients and 376 control patients to be able to reject the null hypothesis that this odds ratio equals 1 with  and <span class="citation">[48]</span>; my planned sample size sample size includes a margin for model stability and incomplete data.<span class="citation">[49]</span></p>
<p>Secondary (exploratory) analysis will investigate gene-environment interaction. The global minor allele frequency of MUC5B rs35705950 is 0.05.<span class="citation">[50]</span> With an estimated prevalence of IPF of 20/100000<span class="citation">[1]</span> and with ORs 2.0 for asbestos exposure and 6.8 for rs35705950<span class="citation">[42]</span>, 113 cases would be required to detect a minimum interaction OR of 4.0.<span class="citation">[51]</span> While I acknowledge that this exploratory analysis will have the power to detect only a large effect size it seems a valuable opportunity to examine an unexplored area in IPF research.</p>
<h2 id="method-4"><span class="header-section-number">7.2</span> Method</h2>
<p>In tincidunt viverra dolor, ac pharetra tellus faucibus eget. Pellentesque tempor a enim nec venenatis. Morbi blandit magna imperdiet posuere auctor. Maecenas in maximus est.</p>
<!-- 
Comments can be added like this.
-->
<h2 id="results-4"><span class="header-section-number">7.3</span> Results</h2>
<p>These are the results. Curabitur vulputate nisl non ante tincidunt tempor. Aenean porta nisi quam, sed ornare urna congue sed. Curabitur in sapien justo. Quisque pulvinar ullamcorper metus, eu varius mauris pellentesque et. In hac habitasse platea dictumst. Pellentesque nec porttitor libero. Duis et magna a massa lacinia cursus.</p>
<h2 id="discussion-4"><span class="header-section-number">7.4</span> Discussion</h2>
<p>possibility of missed chronic HP <span class="citation">[52]</span></p>
<h2 id="conclusion-4"><span class="header-section-number">7.5</span> Conclusion</h2>
<p>This is the conclusion to the chapter. Nulla sed condimentum lectus. Duis sed tempor erat, at cursus lacus. Nam vitae tempus arcu, id vestibulum sapien. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.</p>
<h1 id="conclusion-5"><span class="header-section-number">8</span> Conclusion</h1>
<!-- 
A chapter that concludes the thesis by summarising the learning points
and outlining future areas for research
-->
<h2 id="thesis-summary"><span class="header-section-number">8.1</span> Thesis summary</h2>
<p>In summary, pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Nunc eleifend, ex a luctus porttitor, felis ex suscipit tellus, ut sollicitudin sapien purus in libero. Nulla blandit eget urna vel tempus. Praesent fringilla dui sapien, sit amet egestas leo sollicitudin at.</p>
<h2 id="future-work"><span class="header-section-number">8.2</span> Future work</h2>
<p>chronic hp</p>
<h1 id="appendix-1-ipf-epidemiology-code" class="unnumbered">Appendix 1: IPF epidemiology code</h1>
<p><a href="https://github.com/drcjar/pypf">IPF epidemiology</a></p>
<!-- 
This could be a list of papers by the author for example 
-->
<h1 id="appendix-2-ipfjes-study-documentation" class="unnumbered">Appendix 2: IPFJES study documentation</h1>
<!-- 
This could include extra figures or raw data
-->
<p><a href="https://github.com/drcjar/ipfjes/">IPFJES study documentation</a></p>

<!-- 
Do not edit this page.

References are automatically generated from the BibTex file (References.bib)

...which you should create using your reference manager.
-->
<h1 id="references" class="unnumbered">References</h1>
<div id="refs" class="references">
<div id="ref-Navaratnam2011">
<p>1 Navaratnam V, Fleming K, West J <em>et al.</em> The rising incidence of idiopathic pulmonary fibrosis in the uk. <em>Thorax</em> 2011;<strong>66</strong>:462–7.</p>
</div>
<div id="ref-Maher2012">
<p>2 Maher TM. Idiopathic pulmonary fibrosis: Pathobiology of novel approaches to treatment. <em>Clin Chest Med</em> 2012;<strong>33</strong>:69–83. doi:<a href="https://doi.org/10.1016/j.ccm.2011.11.002">10.1016/j.ccm.2011.11.002</a></p>
</div>
<div id="ref-Ley2013">
<p>3 Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. <em>Clinical epidemiology</em> 2013;<strong>5</strong>:483.</p>
</div>
<div id="ref-Spagnolo2014">
<p>4 Spagnolo P, Grunewald J, Bois RM du. Genetic determinants of pulmonary fibrosis: Evolving concepts. <em>The Lancet Respiratory Medicine</em> 2014;<strong>2</strong>:416–28.</p>
</div>
<div id="ref-Hubbard1998">
<p>5 Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis a population-based cohort study. <em>CHEST Journal</em> 1998;<strong>113</strong>:396–400.</p>
</div>
<div id="ref-Vancheri2010">
<p>6 Vancheri C, Failla M, Crimi N <em>et al.</em> Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. <em>Eur Respir J</em> 2010;<strong>35</strong>:496–504. doi:<a href="https://doi.org/10.1183/09031936.00077309">10.1183/09031936.00077309</a></p>
</div>
<div id="ref-Barber2015">
<p>7 Barber C, Wiggans R, Young C <em>et al.</em> UK asbestos imports and mortality due to idiopathic pulmonary fibrosis. <em>Occup Med</em> 2015;kqv142.</p>
</div>
<div id="ref-Monso1990">
<p>8 Monso E, Tura JM, Marsal M <em>et al.</em> Mineralogical microanalysis of idiopathic pulmonary fibrosis. <em>Arch Environ Health</em> 1990;<strong>45</strong>:185–8. doi:<a href="https://doi.org/10.1080/00039896.1990.9936714">10.1080/00039896.1990.9936714</a></p>
</div>
<div id="ref-Monso1991">
<p>9 Monsó E, Tura J, Pujadas J <em>et al.</em> Lung dust content in idiopathic pulmonary fibrosis: A study with scanning electron microscopy and energy dispersive x ray analysis. <em>Br J Ind Med</em> 1991;<strong>48</strong>:327–31.</p>
</div>
<div id="ref-Glazer2009">
<p>10 Glazer C, Maier L. Occupational interstitial lung disease. <em>Eur Respir Monograph</em> 2009;<strong>46</strong>:265–86.</p>
</div>
<div id="ref-Ghio2014">
<p>11 Ghio A, Sangani R, Roggli V. Expanding the spectrum of particle-and fiber-associated interstitial lung diseases. <em>Turk Toraks Derg</em> 2014;<strong>15</strong>:1–8.</p>
</div>
<div id="ref-Travis2013">
<p>12 Travis WD, Costabel U, Hansell DM <em>et al.</em> An official american thoracic society/european respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <em>American journal of respiratory and critical care medicine</em> 2013;<strong>188</strong>:733–48.</p>
</div>
<div id="ref-Reynolds2017">
<p>13 Reynolds CJ, Blanc PD. Organising pneumonia and other uncommon interstitial disorders. In: <em>Parkes’ occupational lung disorders, fourth edition</em>. 2018. </p>
</div>
<div id="ref-Turner-Warwick1998">
<p>14 Turner-Warwick M. In search of a cause of cryptogenic fibrosing alveolitis (cfa): One initiating factor or many? <em>Thorax</em> 1998;<strong>53</strong>:S3–9.</p>
</div>
<div id="ref-Hubbard2001">
<p>15 Hubbard R. Occupational dust exposure and the aetiology of cryptogenic fibrosing alveolitis. <em>Eur Respir J</em> 2001;<strong>18</strong>:119s–21s.</p>
</div>
<div id="ref-Taskar2006">
<p>16 Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? <em>Proc Am Thorac Soc</em> 2006;<strong>3</strong>:293–8.</p>
</div>
<div id="ref-Gulati2015">
<p>17 Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. <em>Current opinion in pulmonary medicine</em> 2015;<strong>21</strong>:193–200. doi:<a href="https://doi.org/10.1097/MCP.0000000000000144">10.1097/MCP.0000000000000144</a></p>
</div>
<div id="ref-Fontaine2009">
<p>18 Fontaine J-F, Barbosa-Silva A, Schaefer M <em>et al.</em> MedlineRanker: Flexible ranking of biomedical literature. <em>Nucleic acids research</em> 2009;<strong>37</strong>:W141–6. doi:<a href="https://doi.org/10.1093/nar/gkp353">10.1093/nar/gkp353</a></p>
</div>
<div id="ref-Reynolds2017pubmed">
<p>19 Reynolds C, De Matteis S, Cullinan P <em>et al.</em> Pubmed mining for occupational idiopathic pulmonary fibrosis papers. 2017.</p>
</div>
<div id="ref-Scott1990">
<p>20 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. <em>BMJ</em> 1990;<strong>301</strong>:1015.</p>
</div>
<div id="ref-Iwai1994">
<p>21 Iwai K, Mori T, Yamada N <em>et al.</em> Idiopathic pulmonary fibrosis. epidemiologic approaches to occupational exposure. <em>Am J Respir Crit Care Med</em> 1994;<strong>150</strong>:670–5. doi:<a href="https://doi.org/10.1164/ajrccm.150.3.8087336">10.1164/ajrccm.150.3.8087336</a></p>
</div>
<div id="ref-Hubbard1996a">
<p>22 Hubbard R, Lewis S, Richards K <em>et al.</em> Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. <em>The Lancet</em> 1996;<strong>347</strong>:284–9.</p>
</div>
<div id="ref-Mullen1998">
<p>23 Mullen J, Hodgson MJ, DeGraff CA <em>et al.</em> Case-control study of idiopathic pulmonary fibrosis and environmental exposures. <em>J Occup Environ Med</em> 1998;<strong>40</strong>:363–7.</p>
</div>
<div id="ref-Baumgartner2000">
<p>24 Baumgartner KB, Samet JM, Coultas DB <em>et al.</em> Occupational and environmental risk factors for idiopathic pulmonary fibrosis: A multicenter case-control study. collaborating centers. <em>Am J Epidemiol</em> 2000;<strong>152</strong>:307–15.</p>
</div>
<div id="ref-Miyake2005">
<p>25 Miyake Y, Sasaki S, Yokoyama T <em>et al.</em> Occupational and environmental factors and idiopathic pulmonary fibrosis in japan. <em>Ann Occup Hyg</em> 2005;<strong>49</strong>:259–65.</p>
</div>
<div id="ref-Gustafson2007">
<p>26 Gustafson T, Dahlman-Höglund A, Nilsson K <em>et al.</em> Occupational exposure and severe pulmonary fibrosis. <em>Respir Med</em> 2007;<strong>101</strong>:2207–12.</p>
</div>
<div id="ref-Garcia-SanchoFigueroa2010">
<p>27 García-Sancho Figueroa MC, Carrillo G, Pérez-Padilla R <em>et al.</em> Risk factors for idiopathic pulmonary fibrosis in a mexican population. a case-control study. <em>Respir Med</em> 2010;<strong>104</strong>:305–9.</p>
</div>
<div id="ref-Garcia-Sancho2011">
<p>28 García-Sancho C, Buendía-Roldán I, Fernández-Plata MR <em>et al.</em> Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. <em>Respiratory medicine</em> 2011;<strong>105</strong>:1902–7. doi:<a href="https://doi.org/10.1016/j.rmed.2011.08.022">10.1016/j.rmed.2011.08.022</a></p>
</div>
<div id="ref-Awadalla2012">
<p>29 Awadalla NJ, Hegazy A, Elmetwally RA <em>et al.</em> Occupational and environmental risk factors for idiopathic pulmonary fibrosis in egypt: A multicenter case-control study. <em>Int J Occup Environ Med</em> 2012;<strong>3</strong>:107–16.</p>
</div>
<div id="ref-Paolocci2013">
<p>30 Paolocci G, Nicolic V, Folletti I <em>et al.</em> Risk factors for idiopathic pulmonary fibrosis in southern europe: A case-control study. 2013.</p>
</div>
<div id="ref-Koo2017">
<p>31 Koo J-W, Myong J-P, Yoon H-K <em>et al.</em> Occupational exposure and idiopathic pulmonary fibrosis: A multicentre case-control study in korea. <em>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</em> 2017;<strong>21</strong>:107–12. doi:<a href="https://doi.org/10.5588/ijtld.16.0167">10.5588/ijtld.16.0167</a></p>
</div>
<div id="ref-Hubbard1996">
<p>32 Hubbard R, Johnston I, Coultas DB <em>et al.</em> Mortality rates from cryptogenic fibrosing alveolitis in seven countries. <em>Thorax</em> 1996;<strong>51</strong>:711–6.</p>
</div>
<div id="ref-Navaratnam2014">
<p>33 Navaratnam V, Fogarty AW, McKeever T <em>et al.</em> Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: A population-based case-control study. <em>Thorax</em> 2014;<strong>69</strong>:207–15. doi:<a href="https://doi.org/10.1136/thoraxjnl-2013-203740">10.1136/thoraxjnl-2013-203740</a></p>
</div>
<div id="ref-Hubbard2000">
<p>34 Hubbard R, Cooper M, Antoniak M <em>et al.</em> Risk of cryptogenic fibrosing alveolitis in metal workers. <em>The Lancet</em> 2000;<strong>355</strong>:466–7.</p>
</div>
<div id="ref-Welch1994">
<p>35 Welch LS, Michaels D, Zoloth SR. The national sheet metal worker asbestos disease screening program: Radiologic findings. national sheet metal examination group. <em>Am J Ind Med</em> 1994;<strong>25</strong>:635–48.</p>
</div>
<div id="ref-Rake2009">
<p>36 Rake C, Gilham C, Hatch J <em>et al.</em> Occupational, domestic and environmental mesothelioma risks in the british population: A case-control study. <em>Br J Cancer</em> 2009;<strong>100</strong>:1175–83. doi:<a href="https://doi.org/10.1038/sj.bjc.6604879">10.1038/sj.bjc.6604879</a></p>
</div>
<div id="ref-Pinheiro2008">
<p>37 Pinheiro GA, Antao VC, Wood JM <em>et al.</em> Occupational risks for idiopathic pulmonary fibrosis mortality in the united states. <em>Int J Occup Environ Health</em> 2008;<strong>14</strong>:117–23.</p>
</div>
<div id="ref-Caminati2015">
<p>38 Caminati A, Madotto F, Cesana G <em>et al.</em> Epidemiological studies in idiopathic pulmonary fibrosis: Pitfalls in methodologies and data interpretation. <em>European respiratory review : an official journal of the European Respiratory Society</em> 2015;<strong>24</strong>:436–44. doi:<a href="https://doi.org/10.1183/16000617.0040-2015">10.1183/16000617.0040-2015</a></p>
</div>
<div id="ref-Teschke2002">
<p>39 Teschke K, Olshan AF, Daniels JL <em>et al.</em> Occupational exposure assessment in case-control studies: Opportunities for improvement. <em>Occup Environ Med</em> 2002;<strong>59</strong>:575–93; discussion 594.</p>
</div>
<div id="ref-Bourgkard2013">
<p>40 Bourgkard E, Wild P, Gonzalez M <em>et al.</em> Comparison of exposure assessment methods in a lung cancer case-control study: Performance of a lifelong task-based questionnaire for asbestos and pahs. <em>Occup Environ Med</em> 2013;<strong>70</strong>:884–91. doi:<a href="https://doi.org/10.1136/oemed-2013-101467">10.1136/oemed-2013-101467</a></p>
</div>
<div id="ref-Cherrie1999">
<p>41 Cherrie JW, Schneider T. Validation of a new method for structured subjective assessment of past concentrations. <em>Ann Occup Hyg</em> 1999;<strong>43</strong>:235–45.</p>
</div>
<div id="ref-Seibold2011">
<p>42 Seibold MA, Wise AL, Speer MC <em>et al.</em> A common muc5b promoter polymorphism and pulmonary fibrosis. <em>N Engl J Med</em> 2011;<strong>364</strong>:1503–12. doi:<a href="https://doi.org/10.1056/NEJMoa1013660">10.1056/NEJMoa1013660</a></p>
</div>
<div id="ref-Peljto2013">
<p>43 Peljto AL, Zhang Y, Fingerlin TE <em>et al.</em> Association between the muc5b promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. <em>JAMA</em> 2013;<strong>309</strong>:2232–9.</p>
</div>
<div id="ref-Fingerlin2013">
<p>44 Fingerlin TE, Murphy E, Zhang W <em>et al.</em> Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. <em>Nat Genet</em> 2013;<strong>45</strong>:613–20. doi:<a href="https://doi.org/10.1038/ng.2609">10.1038/ng.2609</a></p>
</div>
<div id="ref-Noth2013">
<p>45 Noth I, Zhang Y, Ma S-F <em>et al.</em> Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. <em>Lancet Respir Med</em> 2013;<strong>1</strong>:309–17. doi:<a href="https://doi.org/10.1016/S2213-2600(13)70045-6">10.1016/S2213-2600(13)70045-6</a></p>
</div>
<div id="ref-Raghu2011">
<p>46 Raghu. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, author=Raghu, Ganesh and Collard, Harold R and Egan, Jim J and Martinez, Fernando J and Behr, Juergen and Brown, Kevin K and Colby, Thomas V and Cordier, Jean-François and Flaherty, Kevin R and Lasky, Joseph A and others. <em>Am J Respir Crit Care Med</em> 2011;<strong>183</strong>:788–824.</p>
</div>
<div id="ref-NICE2013">
<p>47 NICE. Idiopathic pulmonary fibrosis: The diagnosis and management of suspected idiopathic pulmonary fibrosis. 2013.<a href="https://www.nice.org.uk/guidance/cg163" class="uri">https://www.nice.org.uk/guidance/cg163</a></p>
</div>
<div id="ref-Dupont1990">
<p>48 Dupont WD, Plummer WD. Power and sample size calculations: A review and computer program. <em>Control Clin Trials</em> 1990;<strong>11</strong>:116–28.</p>
</div>
<div id="ref-Agresti2007">
<p>49 Agresti A. Building and applying logistic regression models. <em>Categorical Data Analysis, Second Edition</em> 2007;211–66.</p>
</div>
<div id="ref-Cariaso2012">
<p>50 Cariaso M, Lennon G. SNPedia: A wiki supporting personal genome annotation, interpretation and analysis. <em>Nucleic Acids Res</em> 2012;<strong>40</strong>:D1308–12. doi:<a href="https://doi.org/10.1093/nar/gkr798">10.1093/nar/gkr798</a></p>
</div>
<div id="ref-Gauderman2002">
<p>51 Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. <em>Am J Epidemiol</em> 2002;<strong>155</strong>:478–84.</p>
</div>
<div id="ref-Morell2013">
<p>52 Morell F, Villar A, Montero M-Á <em>et al.</em> Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: A prospective case-cohort study. <em>Lancet Respir Med</em> 2013;<strong>1</strong>:685–94. doi:<a href="https://doi.org/10.1016/S2213-2600(13)70191-7">10.1016/S2213-2600(13)70191-7</a></p>
</div>
</div>
            </body>
</html>

